<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265016</url>
  </required_header>
  <id_info>
    <org_study_id>RBC in CAD</org_study_id>
    <secondary_id>13-037</secondary_id>
    <nct_id>NCT02265016</nct_id>
  </id_info>
  <brief_title>Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease</brief_title>
  <official_title>Regulation and Signaling of RBC-eNOS in Patients With Stable and Unstable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is measurement of expression and activity of RBC eNOS in different
      clinical cohorts of patients with coronary artery disease and acute coronary syndrome and to
      investigate the importance of the NO-stimulated reaction cascade in terms of sGC and PKG.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of red cell endothelial nitric oxide-synthase (eNOS)-expression and - activity</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deformability and stability of red blood cell membrane</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>by Laser assisted Optical Rotational Cell Analyzer (LORCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular function</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of microvascular function with Laser-Doppler Perfusion Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral and central hemodynamic measurement</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of arterial stiffness</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of arterial stiffness with pulse wave analysis during blood pressure measurement or echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of flow-mediated dilation</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of nitrate and nitrite in blood plasma and red blood cells (RBC)</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of nitric oxide and cyclic guanosine monophosphate (cGMP) in blood plasma and in red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of endothelial microparticles</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging and turnover of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Redox status of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of redox status of red blood cells will be measured on free thiole with thioltracker and reactive oxygen species( ROS) by dihydrodichlorofluorescein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggregation of red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>Determination of aggregation of red blood cells with LORCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregometry</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression and function of soluble guanylyl cyclase (sGC) in red blood cells</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>measurement of enzyme expression and activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression and activity of Protein Kinase G (PKG)</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>measurement of enzyme expression and activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of leucocyte populations and leucocyte function</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
    <description>flow-cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of tetrahydrobiopterin-metabolism</measure>
    <time_frame>baseline, 3 hours and 3 month</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Endothelial NO-synthase</condition>
  <arm_group>
    <arm_group_label>Patients with CAD</arm_group_label>
    <description>Patients with stable coronary artery disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with ACS</arm_group_label>
    <description>Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy control group</arm_group_label>
    <description>healthy control group without clinical apparent arteriosclerosis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        3 groups:

          -  ACS group (100 Patients)

          -  stable CAD group (100 Patients)

          -  healthy control group (100 Healthy Volunteers)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  for ACS(acute coronary syndrome)-Group: angiographic coronary artery disease; acute
             coronary syndrome, defined by EITHER unstable angina pectoris with significant
             coronary stenosis (troponin negative, without significant ST-elevation) OR low-risk
             NSTEMI (Troponin positive, without significant ST-elevation)

          -  for stable CAD-Group: angiographic coronary artery disease; no acute coronary syndrome
             within the last 3 months

          -  healthy control group: No clinical or angiographical signs of apparent atherosclerosis

        Exclusion Criteria:

          -  acute inflammation (CRP &gt; 1 mg/dl, leukocyte &gt; 11.000/Âµl)

          -  malignant diseases

          -  pregnancy

          -  medication with NO-donors ( e.g.isosorbide mononitrate, isosorbide dinitrate, glyceryl
             trinitrate, Molsidomin, Ranexa)

          -  patients with STEMI or high-risk NSTEMI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malte Kelm, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Pneumology and Angiology, University Hospital Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Cortese-Krott, PhD</last_name>
    <email>Miriam.Cortese@uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georg Wolff</last_name>
    <email>Georg.Wolff@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Cortese-Krott, PhD</last_name>
      <email>Miriam.Cortese@uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg Wolff</last_name>
      <email>Georg.Wolff@med.uni-duesseldorf.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>angina pectoris</keyword>
  <keyword>non-ST-segment elevation myocardial infarction</keyword>
  <keyword>red blood cells</keyword>
  <keyword>erythrocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

